Fundraising FoxOmega Funds — 2018 Investments
3 investments dated 2018 · listed companies and verified rows first · show all
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)
Co-investorsARCH Venture PartnersBay City CapitalEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Pivotal Life Sciences+3 more
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inRandall Stanicky(Executive Officer)inAnthony Costello(Director)Bruce Robertson(Director)Douglas Langa(Director)
BoardAlex Zisson(Director)
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesRevelation Partners+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.